Blog

  • Trump and Mike Johnson are desperately attempting to save lots of the Home of Representatives earlier than Virginia votes on a brand new map

    Trump and Mike Johnson are desperately attempting to save lots of the Home of Representatives earlier than Virginia votes on a brand new map

    Virginia could be the next domino to fall Trump’s epic failure to rig the midterm elections.

    Donald Trump, the “stable genius” who devised a plan to keep the House of Representatives under Republican control by getting red states to redraw their maps, is teaming up with his No. 1 lackey, House Speaker Mike Johnson, to try to lure Republicans to the polls to take part in tomorrow’s election in Virginia that could give Democrats four additional House seats in November.

    Alex Isenstadt of Axios posted on

    Trump is apparently so lazy that he couldn’t actually be persuaded to hold a rally in Virginia to get the vote, but there are a few important factors behind this.

    Donald Trump doesn’t want to be blamed for the redistricting loss if the new map passes, so he’ll stay away.

    Democrats must have hoped that Trump would show up in the state because he is deeply despised in Virginia.

    Trump DOGE layoffs cost Virginia 23,500 jobs, but the economic impact was much worse.

    VPM Media reported:

    On average, each federal government employee earns about 1.6 times as much as the average private sector employee,” said Bob McNab, chair of the economics department at Old Dominion University. “When we factor in benefits, that ratio jumps to two.” The loss of 23,500 federal government jobs last year in Virginia is roughly equivalent to the loss of 47,000 private sector jobs.”

    At the moment it looks like Trump and Johnson will have a tough fight in Virginia.

  • Tim Prepare dinner’s reactions: Trump, Altman, Buffett on Apple CEO change

    Tim Prepare dinner’s reactions: Trump, Altman, Buffett on Apple CEO change

    Apple CEO Tim Cook holds an iPhone 17 Pro and an iPhone Air as Apple holds an event at the Steve Jobs Theater on its campus in Cupertino, California, United States, on September 9, 2025.

    Manuel Orbegozo | Reuters

    Apple announced Monday that CEO Tim Cook will be replaced by John Ternus. Executives across the tech industry and beyond began reacting to the transition shortly after the news broke.

    Cook served as CEO of the iPhone maker for nearly 15 years after late founder Steve Jobs stepped down in 2011.

    President Donald Trump praised Cook’s tenure in a Truth Social post early Tuesday, saying, “It started with a phone call from Tim at the start of my first term.”

    “Tim Cook has had an AMAZING career, almost unparalleled, and he will continue to do great work for Apple and whatever else he works on. Quite simply, Tim Cook is an incredible guy!!!” Trump wrote.

    Trump continued to praise Cook’s work on CNBC’s “Squawk Box” Tuesday morning.

    “I got to know him very well,” Trump said. “He’s a fantastic person, he did an incredible job.”

    “Tim Cook is a legend,” OpenAI CEO Sam Altman wrote on X. “I am very grateful for everything he has done, and I am very grateful for Apple.”

    Apple and OpenAI first partnered in 2024, integrating ChatGPT into Siri and Apple’s writing tools.

    Oculus VR founder Palmer Luckey also posted on X and wrote, “RIP Tim Apple,” referencing the famous Trump White House incident in 2019.

    During his first term, Trump incorrectly addressed Cook as “Tim Apple.” Cook made light of the comment and replaced his last name with the Apple logo on his Twitter profile.

    Luckey left Facebook in 2017 and founded defense company Anduril later that year.

    Berkshire Hathaway Chairman Warren Buffett told CNBC’s Becky Quick, “Without Tim Cook, Apple wouldn’t be the Apple it is today.”

    “What he did with Apple was something no one I know could do,” Buffett said. Apple is Berkshire Hathaway’s largest holding.

    “He covers the world, deals with countries with diverse histories and acts well towards the customer, the people who have worked for him, most importantly the shareholders that we were fortunate to be one of…he is one of a kind,” Buffett said.

    Ternus, currently senior vice president of hardware engineering, will become CEO effective September 1. Cook will then assume the role of Executive Chairman.

    Choose CNBC as your preferred source on Google and never miss a moment from the most trusted name in business news.

  • Trump’s Government Order on Psychedelics and What It Means for Hashish

    Trump’s Government Order on Psychedelics and What It Means for Hashish

    Advocates attend a press conference about the “Impact of Incarcerating Individuals Accused of Marijuana Offenses” and policy reform ideas in front of the U.S. Capitol on April 20, 2026.

    Tom Williams | CQ Roll Call, Inc. | Getty Images

    A White House executive order on psychedelics signed by President Donald Trump on Saturday aims to accelerate research into drugs like psilocybin, MDMA and ibogaine, helping to legitimize an industry that has long been largely underground.

    But it also raises a larger question: Will psychedelics, like cannabis, fall victim to a slow-moving federal lawsuit?

    The latest executive order comes about four months after an attempt by President Trump to reclassify cannabis, opening the door to greater research and investment opportunities. But since that policy, progress toward reclassifying cannabis has largely stalled as review by the Drug Enforcement Administration continues and no final decision has been made on moving marijuana from Schedule I to the lower Schedule III.

    The delay reflects that drug policy often slows once it enters regulatory review, where scientific assessment, legal standards and policy converge.

    “The process was certainly slow and frustrating for those involved, considering they fought for decades against the outrageous misclassification of marijuana in the 1970s,” said Shawn Hauser, partner at cannabis law firm Vicente LLP.

    Vicente LLP also serves as legal counsel for the National Compassionate Care Council (NCCC), a coalition of healthcare stakeholders focused on evidence-based cannabis policy.

    However, psychedelic regulation is focused on accelerating research rather than legalization. It directs agencies such as the U.S. Food and Drug Administration to expand clinical trials and “right to try” access for patients with serious mental illnesses while leaving drug scheduling unchanged.

    Atai Beckley is among a number of psychedelic-focused drug developers whose shares have been rising since the order was signed over the weekend, rising about 25% on Monday. Several smaller cap stocks also surged, including Compass paths, Definium Therapeutics and US-listed shares of Cybin.

    Hauser said the recent psychedelics regulation reflects a broader shift in Washington toward a medically-focused framework and could provide a path forward for cannabis re-planning.

    “The science-first, patient-first and healthcare-first approach is currently gaining ground in Washington,” she said.

    “The psychedelic pathway – based on physician-led protocols, clinical research and compassionate use frameworks – is indeed a model that cannabis advocates should investigate and adopt more aggressively,” Hauser said.

    Safety comes first

    Trump’s psychedelics measure has drawn particular attention because it contains ibogaine, a powerful, naturally occurring psychoactive compound with long-standing safety concerns.

    The drug is currently being studied for use in post-traumatic stress disorder, depression and addiction, but the cardiac risks raised by Nora Volkow of the National Institute on Drug Abuse remain a major obstacle.

    This tension is exacerbated by the expansion of “Right to Try” access, a federal law that allows patients diagnosed with life-threatening diseases or conditions to try experimental drugs if no other treatments work. This distinction usually only applies after Phase I trials have been successful.

    Ibogaine has struggled to meet these criteria because most of the research on this drug has been conducted outside the United States

    Psychedelic industry leaders say the order is meaningful, but the full impact remains unknown until implementation catches up and the scientific value is proven.

    “The opportunity now lies not in hype, but in execution: rigorous science, disciplined safety standards, physician-led protocols and real outcomes data,” said Tom Feegel, CEO of clinical neurohealth center Beond.

    Beond, based in Cancun, Mexico, specializes in ibogaine therapy.

    Feegel added that while the executive order signals legitimacy at the highest levels of government, the next phase is crucial.

    There is still no commercial market for psychedelics, although clinical-stage developers such as AtaiBeckley, Compass and GH Research are establishing themselves. Many are prioritizing research into less controversial psychedelics such as psilocybin and MDMA derivatives to treat mental illness.

    The US states have also weighed the space. Colorado moved forward with regulated access to psychedelic drugs for its residents in 2022, while a ballot measure in Massachusetts failed in 2024 with 56% of voters rejecting access.

    According to the deal, cannabis already has a multi-billion-dollar adult-use industry in dozens of states, giving it a significant head start, although federal regulation remains unclear.

    Hauser argued that the two industries ultimately reinforced each other.

    “The two regulatory pathways are not in conflict,” she said. “Both promote the broader legitimacy of plant-based alternative medicine, and the infrastructure built for one will inevitably support the other.”

    Choose CNBC as your preferred source on Google and never miss a moment from the most trusted name in business news.

  • Alan Osmond, The Osmonds singer, dies at 76

    Alan Osmond, The Osmonds singer, dies at 76

    The Osmonds mourning the loss of one of their relatives.

    Alan OsmondThe oldest member of the barbershop quartet, born in Utah in the 1970s, died on the evening of April 20, his family confirmed. He was 76.

    “It is with deep sadness that we share the death of my beloved brother Alan Osmond.” Merrill Osmond72, wrote in a statement from People. “I was grateful to be with him shortly before his death and to share one last meaningful moment together. Alan was a gifted creator, a man of faith, and a deeply loving soul whose life blessed many.”

    Born at George Osmond And Olive Osmond In 1949, Alan was the oldest in the band, which also consisted of the Merrill brothers, Jay Osmond71 and Wayne Osmondwho died last year at the age of 73.

    Later, brothers Donny Osmond68, and Jimmy Osmond63, also joined the group as they continued to develop their sound. (The Osmond siblings also include Virl Osmond80, Tom Osmond78 and Marie Osmond68, although they did not perform in the family band.)

  • UnitedHealth Group (UNH) Q1 2026 outcomes

    UnitedHealth Group (UNH) Q1 2026 outcomes

    UnitedHealthcare’s sign is displayed at its office building in Minnetonka, Minnesota, USA on December 11, 2025.

    Tim Evans | Reuters

    UnitedHealth Group on Tuesday reported first-quarter profit that beat estimates and raised its 2026 profit outlook as the company can better manage high medical costs and streamline its operations.

    The nation’s largest private insurer said it expects adjusted profit of more than $18.25 per share in 2026, up from a previous forecast of more than $17.75 per share. UnitedHealth is sticking to its full-year revenue forecast of more than $439 billion, which the company said in January reflects “right-sizing across the business.”

    Here’s what the company reported for the first quarter compared to Wall Street’s expectations, based on an analyst survey from LSEG:

    • Earnings per share: $7.23 adjusted vs. $6.57 expected
    • Revenue: $111.72 billion versus expected $109.57 billion

    UnitedHealth is relying on a new leadership team to implement a turnaround plan. The strategy includes reducing membership, selling the UK business of its Optum healthcare unit, investing heavily in artificial intelligence, optimizing access to healthcare and increasing transparency to restore profitability – and the company’s reputation – after a series of hurdles over the past two years.

    The company reported first-quarter net income of $6.28 billion, or $6.90 per share, compared with $6.29 billion, or $6.85 per share, in the same period last year. Excluding items such as divestitures, restructuring and the expected reduction in reserves for unprofitable contracts, UnitedHealth earned $7.23 per share.

    Sales rose to $111.72 billion from $109.58 billion in the same quarter last year. According to StreetAccount, the company’s insurer, UnitedHealthcare, and Optum both beat analysts’ revenue estimates for the quarter.

    In particular, UnitedHealth appears to have a better handle on higher medical costs, an issue that has plagued the entire insurance industry for more than two years. Insurers, particularly those that manage private Medicare plans, have been burdened by the influx of care seekers, the post-pandemic delay and expensive specialty drugs like GLP-1, among other factors.

    More CNBC Health coverage

    UnitedHealth’s medical claims ratio – a measure of total medical costs paid relative to premiums collected – was 83.9% in the first quarter. This is an improvement over the 84.8% reported in the same period last year. A lower ratio typically indicates that the company collected more in premiums than it paid out in benefits, leading to higher profitability.

    According to StreetAccount, analysts expected a rate of 85.5% for the quarter.

    In a press release, UnitedHealth said its first-quarter ratio reflected strong medical expense management and the release of previously deferred funds for unprofitable Optum contracts. However, this improvement was partially offset by “continued elevated” medical costs, the company noted.

    “We continue to help simplify and modernize health care for the people and providers we serve, providing greater value, affordability, transparency and connectivity,” UnitedHealth CEO Stephen Hemsley said in the release.

    The results come just weeks after the Trump administration finalized a payment rate increase for Medicare Advantage plans through 2027 that was far larger than initially proposed, boosting UnitedHealth and other health insurer stocks.

    Choose CNBC as your preferred source on Google and never miss a moment from the most trusted name in business news.

  • JD Vance visits Hungary to assist Viktor Orbán

    JD Vance visits Hungary to assist Viktor Orbán

    Hungary’s Prime Minister Viktor Orban attends a bilateral luncheon hosted by US President Donald Trump at the White House in Washington, DC, USA, on November 7, 2025.

    Jonathan Ernst | Reuters

    Hungarian Prime Minister Viktor Orbán enjoys the “full and unconditional support” of US President Donald Trump – but is on track to lose the country’s election, which is shaping up to be one of the most important and contentious in Europe this year.

    On Tuesday, US Vice President JD Vance will land in Hungary to offer his support to Orbán and address a campaign rally at a soccer stadium in Budapest ahead of Sunday’s election. While other European leaders have clearly sided with Ukraine in their war against Russia, Orbán maintains comparatively close relations with Russian President Vladimir Putin. During the election campaign, he even said that the EU posed a greater threat to Hungary than Russia.

    The latest polls show that Orbán and his Fidesz party are expected to lose to their main opponent, the pro-European opposition Tisza party, whose leader Peter Magyar is on track to replace Orbán after 16 years in power.

    It would be a significant change in a country where discussions are dominated by concerns about migration, vulnerability to higher energy prices, corruption and breaches of the rule of law.

    These violations have led to the European Commission suspending EU funds to the country – around 17 billion euros in funds are still frozen.

    Magyar said releasing funds was his “top priority” and has signaled he is open to closer ties with the EU, including with a view to a possible introduction of the euro.

    In an interview with the Associated Press over the weekend, Magyar said “finding compromises” is an “art.”

    He added: “The world seems to be passing Europe by. Europe has lost its competitiveness. Europe does not have enough strong leaders. There are no leaders with vision and Europe is lagging behind.”

    Lawyer and former government insider Peter Magyar speaks to people during a demonstration he organized in front of the Prosecutor General’s Office on March 26, 2024 in Budapest, Hungary.

    Jano’s grief | Getty Images News | Getty Images

    According to an analysis by the German Marshall Fund, Magyar’s premiership could mark a departure from Orbán’s confrontational foreign policy – and also bring Budapest closer to its Western allies on other issues, such as unity against Russia.

    But a possible Magyar government would not be a clear break with the policies of the Orbán era.

    Migration remains a contentious issue – as does support for Ukraine. Tisza has taken a cautious stance on Ukraine’s EU ambitions – even supporting Orbán’s government in the European Parliament by voting against sending troops or weapons to the front.

    Energy also remains a sensitive issue. Hungary is currently in a dispute with Ukraine over oil supplies via the Druzhba pipeline, which led to Budapest vetoing a €90 billion loan from the EU.

    In recent weeks, Orbán has focused on allaying fears of an energy price shock stemming from the war in Iran. He accused Magyar of conspiring with the EU and Ukraine to cut Hungary off from cheap Russian oil.

    The election campaign was also closely watched for possible Russian interference, with particular focus on reports of misinformation on social media.

    Choose CNBC as your preferred source on Google and never miss a moment from the most trusted name in business news.

  • Polymarket withdraws wager on rescue mission in Iran

    Polymarket withdraws wager on rescue mission in Iran

    Polymarket has removed a forum related to the rescue mission of U.S. military personnel amid political pressure, the latest sign of increasing scrutiny of prediction markets.

    U.S. and Iranian forces are searching for a missing American airman after his F-15E fighter jet was shot down over Iran on Friday. One crew member was rescued, another is unaccounted for.

    Rep. Seth Moulton, D-Mass., criticized the Polymarket site that allowed users to bet on what day the U.S. would confirm the rescue of the two airmen after an American F-15E fighter jet was shot down over Iran. Lawmakers called the site “disgusting” in an X post.

    “They could be your neighbor, a friend, a family member,” Moulton wrote Friday. “And people are betting on whether they will be saved or not.”

    In a response to

    “It should not have been published and we are investigating how this was able to get past our internal safeguards,” Polymarket wrote.

    In a separate X post, Polymarket said it “does not make money or charge fees in any geopolitical markets.”

    In an email to CNBC, Moulton said: “Polymarket did not close this market because it violated their standards. They closed it because we reported them.”

    Moulton also said that the Commodity Futures Trading Commission has the power to regulate prediction market platforms but is doing nothing.

    “That too has to change,” he said. “Yesterday there were 219 active bets in Polymarket’s War category. Today there are 223. This is spreading and Congress must act.”

    Last month, Moulton banned his employees from using prediction market platforms such as Polymarket or Kalshi, a policy his office says is the first of its kind in Congress.

    “The voters we serve should trust that we are making decisions based on the right actions for our nation, not based on the possible outcomes of the bets,” Moulton said Monday on CNBC’s “Squawk Box.”

    Moulton also said on

    Requests for comment from Trump Jr. were not immediately returned to CNBC.

    The Massachusetts lawmaker is part of a growing chorus of voices in Washington calling for greater oversight of these betting platforms amid rising interest.

    A group of Democrats in Congress introduced legislation late last month that would ban prediction markets from allowing betting on elections, war and government actions in addition to sports.

    In February, six Democratic senators called on the Commodity Futures Trading Commission to clarify that it would ban all contracts related to a person’s death. These contracts “pose dangerous risks to national security,” the lawmakers wrote.

    The CFTC announced lawsuits Thursday against three states for what it said were attempts to circumvent the organization’s sole regulatory authority over prediction markets.

    The NFL has also asked prediction market operators to keep certain event contracts that the league deems “offensive bets” off their platforms. The league cited examples of event contracts that could be easily manipulated, were inherently offensive, related to execution and were detectable in advance – and urged operators to refrain from offering such deals.

    —CNBC’s Dan Mangan, Azhar Sukri and Luke Fountain contributed to this report.

    Disclosure: CNBC and Kalshi have a business relationship that includes customer acquisition and minority ownership.

  • Trump is getting ready drug tariffs of as much as 100%

    Trump is getting ready drug tariffs of as much as 100%

    The Trump administration on Thursday imposed new tariffs on brand-name drugs from drug companies that have not reached agreements with the president to lower their U.S. drug prices – a long-awaited move that is likely to affect only a small fraction of drugmakers.

    “We need to ensure that our drug supply is protected, safe and domestic,” a senior government official, who did not want to be named, told reporters on Thursday. “That’s what we do.”

    Also on Thursday, the Trump administration changed how tariffs are calculated on imported steel, aluminum and copper raw materials, as well as imported products containing those metals.

    Patented drugs and their active ingredients are subject to a 100 percent duty rate under the drug plan, but there are options for drugmakers to reduce or avoid the duties, the official said.

    The government will impose a 20% tariff on companies planning onshore production, which would rise to 100% in four years. Drug manufacturers that have fully entered into drug pricing agreements or are currently negotiating with the Department of Health and Human Services and are setting up production domestically would be exempt from the tariffs. New domestic facilities must be completed by January 2029 to qualify, the official said.

    Larger drugmakers have 120 days before the 100 percent tariff takes effect, the official said, but the government expects more companies to announce retraining plans by then. Smaller drugmakers that rely on contract manufacturers have 180 days before this rate is reached.

    The Trump administration is preparing to impose drug tariffs of up to 100% on some imported drugs

    Meanwhile, some countries that have major trade deals with the U.S. will face different drug levies, with a 15% rate in place in the European Union, Japan, Korea and Switzerland. The U.K. will face a 10% tariff partly because the government has increased drug prices, the official said.

    “In these countries, production can stay in these countries because they have a major trade agreement with America,” the official said.

    Genetic products, biosimilars and related ingredients are not currently subject to tariffs, but that will be reassessed in a year, the White House said in a briefing note.

    Certain specialty pharmaceuticals, including those for animal health and the treatment of rare diseases, will be exempt from duties if they come from countries with trade agreements or “meet an urgent public health need,” the fact sheet says.

    The plan marks another shift in Trump’s aggressive trade strategy, more than a month after the Supreme Court struck down global levies he introduced in 2025 that excluded the pharmaceutical industry. The sector-specific tariffs follow a Commerce Department investigation that found certain drug imports posed a national security risk to the United States.

    U.S. President Donald Trump (center) speaks alongside Secretary of Health Robert F. Kennedy Jr. (R) and National Institutes of Health (NIH) Director Jayanta Bhattacharya (L) during a press conference on prescription drug prices in the Roosevelt Room of the White House on May 12, 2025 in Washington, DC

    Jim Watson | Afp | Getty Images

    Since November, more than a dozen major drugmakers, including Eli Lilly, Pfizer And Novo Nordiskhave reached agreements with Trump to lower the prices of new and existing drugs. These agreements are part of the president’s “most favored nation” policy, which pegs drug prices in the U.S. to cheaper ones abroad and exempts companies from tariffs for three years.

    The Trump administration official said 13 companies have already signed a drug pricing agreement, while negotiations are progressing with another four drugmakers. There has already been $400 billion in commitments to the sector during Trump’s time in office to restart manufacturing, the official added.

    Before the groundbreaking drug pricing agreements, Trump repeatedly threatened tariffs on pharmaceutical imports. Those threats—and efforts to curry favor with the president—triggered a new wave of U.S. manufacturing investment from the pharmaceutical industry. These commitments come at a time when domestic drug production has declined significantly.

    In the separate metals tariff measure, the tariff on steel, aluminum and copper raw materials – such as aluminum sheets or steel coils – remains at 50%, but applies to the full price paid by U.S. importers.

    The senior administration official said during a call with reporters Thursday that the adjustment was being made to prevent foreign sellers from underpricing their products to pay less in tariffs.

    Imported finished products that contain more than 15% of these metals will now be subject to a 25% duty on the total value of the item. The previous duty was only 50% on the value of the metal in the product.

    No duty is charged on finished products containing less than 15% of these metals.

    A senior government official said the changes in tariffs on the metals are unlikely to affect the cost of goods, but estimates from non-governmental organizations suggest they will slightly increase the effective tariff rate.

    The Committee for a Responsible Federal Budget estimates the change will result in $70 billion in additional federal revenue over the next decade.

    —CNBC’s Megan Cassella contributed to this article.

    Choose CNBC as your preferred source on Google and never miss a moment from the most trusted name in business news.

  • Trump’s tariffs prompted firms to take out high-interest loans

    Trump’s tariffs prompted firms to take out high-interest loans

    A Main Street Alliance protester holds a sign in front of the U.S. Supreme Court, during which justices will hear oral arguments on President Donald Trump’s attempt to uphold sweeping tariffs after lower courts ruled that Trump overstepped his authority, in Washington, Nov. 5, 2025.

    Nathan Howard | Reuters

    Some small businesses left footing the bill for President Trump’s new tariffs are taking out high-interest merchant cash advances and other forms of debt to cover these additional costs.

    And several business owners who have taken on this costly debt told CNBC they fear financial disaster as a result.

    Companies that spoke to CNBC reported being offered unfavorable loan interest rates of over 30% to cover their plan-related costs.

    These people say their companies could be in a deep financial hole even if the Supreme Court upholds lower federal courts’ rulings that the new tariffs are illegal and orders the federal government to refund companies for tariffs they have already paid.

    U.S. Customs and Border Protection announced earlier this week that it had collected more than $200 billion in tariffs this year as a result of new tariffs imposed by Trump.

    Some of the lending involves merchant cash advances and revenue purchase agreements, which are not regulated by the Federal Deposit Insurance Corporation and are not required to adhere to federal lending standards.

    The FDIC, which has a regulatory policy on predatory lending, declined to comment. The Consumer Financial Protection Bureau, which the Trump administration is trying to dismantle, did not respond to CNBC’s request for comment.

    Josh Esnard, CEO of The Cut Buddy, a shaving products company, said he receives several calls every day from lenders offering high interest rates.

    “They are very aggressive and deceptive when it comes to contacting both by phone and email,” Esnar told CNBC.

    Esnard said even if the Supreme Court finds the tariffs illegal and his company gets a refund, the money won’t cure Cut Buddy.

    Esnard originally used three different lenders to pay its rates, with interest rates on its merchant loans ranging from 24% to 30%. CNBC reviewed these agreements.

    To be considered for the loans, Esnard paid underwriting fees totaling $30,000 in addition to the loans themselves.

    Esnard borrowed a total of $950,000 in the three loans to pay duties totaling $800,000.

    “I needed a $150,000 cushion for my labor and overhead costs until I received payment from retailers and customers for my product,” Esnard said.

    “It will take us five years to pay off this loan, so it’s still a loss.”

    In an agreement, Esnard received a $250,000 loan but owes $325,000 due to fees.

    “I have to pay them back weekly,” he said, citing the agreement.

    Esnard recently received a financial lifeline to stop his high interest payments through a loan from the Business Consortium Fund, which focuses on minority and small businesses.

    The fund reviewed its high-interest loans and approved a new loan to deposit those payments for Esnard.

    “Instead of a weekly payment of $35,000, I now pay $35,000 a month,” Esnard said.

    “Yes, it’s still high, but it’s better than the predatory payments from lenders,” he said.

    “It saved my business from closing. We literally talked to business brokers about selling the business.”

    The Cut Buddy, who appeared on the television show “Shark Tank” in 2017, sells products online and at major retailers such as Walmart, Goal And CVS.

    Esnard said: “2025 would be my highest sales and net income year.”

    “Not anymore, the tariffs have destroyed it,” he said.

    Joann Cartiglia, owner of Queen’s Treasures, a Ticonderoga, New York-based toy company that designs and manufactures historically inspired, handcrafted doll furniture, said she had to take out loans that changed her business exit strategy.

    “We had planned to retire in two years,” said Cantiglia, 64.

    “My husband and I invested a lot of our retirement money in this company, and now I have absolutely no hope of retiring,” she said.

    Her company, which specializes in “Little House on the Prairie” dolls, furniture and clothing, was excited when the year began with the announcement of a relaunch of the television series popular in the 1970s and 1980s.

    However, the new tariffs forced Queen’s Treasures to increase prices on the Laura Ingalls Little House character doll and other items.

    Limited quantities are also an issue across the product range and sales are down 33% due to a lack of stock.

    “I now have loans to cover my business expenses,” Cantiglia said. “My credit score is now down and the banks don’t even care about me because of this lower credit score. I’m forced to take out loans wherever I can.”

    She described the loans her company pays as “mafia interest.”

    “At over 20%, it’s obscenely high,” Cantiglia said. “It is very hard to imagine lenders making record profits from a bad situation.”

    “This was supposed to be a year of development. Now it’s not like that anymore.”

    Even if the Supreme Court declares the tariffs illegal, it won’t solve her company’s cash flow problems, she says.

    “We are 100% in trouble because of the combination of a decline in profitable orders and business operations collapsing,” Cantiglia said.

    “The money we paid in tariffs should have gone toward business operations and stockpiling for the holidays,” she said.

    “I honestly feel like the government is putting me out of business. The tariffs are an anti-American dream.”

    Utah-based Village Lighting Co. said its bill for import duties on the 100 shipping containers it ordered this year is nearly $1 million.

    “About 50% of our sales are based on agreements with our customers, so we sold a lot of that merchandise directly to them at a loss,” said Jared Hendricks, co-owner of Village Lighting, which has been in business for 23 years.

    The company places holiday orders a year in advance, meaning it hasn’t factored in the cost of Trump’s new tariffs, most of which weren’t announced until April.

    “We’ve kind of gone from working for profits to working for tariffs,” Hendricks said.

    “We are only in business to pay off our customs debts and then we look ahead to next year.”

    Although his company was able to take out a loan from his bank to cover customs duties and operating costs, the company had to increase prices and has seen a decline in sales ever since.

    “The modest price increases resulted in significant sales declines and forced us to discount products just to move inventory,” Hendricks said.

    “At this point, it is becoming increasingly difficult to cover the cost of tariffs through normal product sales.”

    Hendricks also said potential refunds resulting from a Supreme Court ruling are not a panacea for distressed companies.

    “This experience shows that tariffs are not sustainable,” he said. “Consumers cannot absorb these higher prices and the burden shifts entirely to the importer. This dynamic threatens the survival of companies like ours.”

    Choose CNBC as your preferred source on Google and never miss a moment from the most trusted name in business news.

  • Jamie Raskin has the right response to Pam Bondi’s firing

    Jamie Raskin has the right response to Pam Bondi’s firing

    House Judiciary Committee Ranking Member Jamie Raskin (D-MD) has been an outspoken critic of Pam Bondi and the Trump Justice Department and has sought to hold the Justice Department accountable.

    Raskin sparred with Bondi during the hearings, and the constitutional scholar made it clear how outraged he was at what she did to the Justice Department at Donald Trump’s direction.

    PoliticusUSA is 100% independent and bows to no one. Support us by becoming a subscriber.

    Rep. Raskin had a lot to say after Bondi was fired by Trump:

    TToday, President Trump fired Attorney General Pam Bondi, ending a term that will be remembered as a grave betrayal not only of the Justice Department, but of the American people the department serves. As a reminder, the DOW was below 50,000.

    The attorney general has the best legal job in America. The mission is justice, and the customers are the American people. But Pam Bondi gave up on this mission, indeed, she never accepted it. She never served as anything other than Donald Trump’s personal criminal defense and personal injury attorney, turning the people’s Justice Department into the president’s private instrument of revenge, targeting his critics with a bureaucratic vendetta while scuttling justice for his favored political friends and allies.

    Their legacy of failure begins with the egregious purge of prosecutors who investigated Trump’s pet crimes, including those committed by the Jan. 6 cop thugs and insurrectionists and by Trump himself. Career civil servants were forced out of the Justice Department not for violating the law, but for complying with it. The purge of real prosecutors has corrupted the Justice Department and compromised the safety of all Americans.

    This shameful legacy is cemented by their grotesque misuse of the Epstein files. She carried out a historic and egregious cover-up directly from the Justice Department. Investigations against co-conspirators were closed. It withheld three million pages of documents in defiance of the law. The names of the perpetrators, supporters, accomplices and co-conspirators were removed from public view, while the identities of the victims were made available to the public. Under Bondi, the perpetrators were coddled and the survivors were pushed into the background.

    Read more from Raskin below.